Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (281-290 of 868) with videos related to

Pageof 87
Sort By:
Cancer Research|May 17, 2003
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusionEnrica Orsini, Roberto Bellucci, Edwin P Alyea, et al.
Blood|November 17, 2007
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita Singh, Mohan Brahmandam, et al.
Oncology (Williston Park, N.Y.)|September 6, 2011
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasiasPaul G Richardson, Jacob Laubach, Constantine S Mitsiades, et al.
Haematologica|August 2, 2014
The challenge of cross-trial comparisons using limited dataJacob P Laubach, Edward A Faber, Peter Voorhees, et al.
JACC. Advances|October 28, 2025
Prevalence of Sleep Apnea and Echocardiographic Correlates in a Community-Based Cohort of Cardio-Oncology PatientsMini K Das, John L Huber, Jamie D Kemp, et al.
Cancer Research|September 6, 2005
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cellsMikael Altun, Paul J Galardy, Reshma Shringarpure, et al.
Oncogene|April 20, 2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Dharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2013
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cellsDharminder Chauhan, Arghya Ray, Kristina Viktorsson, et al.
Oncotarget|November 9, 2017
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.
Cancer Research|June 17, 2006
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132Lisa J A Crawford, Brian Walker, Huib Ovaa, et al.
Pageof 87

Showing results (281-290 of 868) with videos related to

Sort By:
Pageof 87
Cancer Research|May 17, 2003
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusionEnrica Orsini, Roberto Bellucci, Edwin P Alyea, et al.
Blood|November 17, 2007
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita Singh, Mohan Brahmandam, et al.
Oncology (Williston Park, N.Y.)|September 6, 2011
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasiasPaul G Richardson, Jacob Laubach, Constantine S Mitsiades, et al.
Haematologica|August 2, 2014
The challenge of cross-trial comparisons using limited dataJacob P Laubach, Edward A Faber, Peter Voorhees, et al.
JACC. Advances|October 28, 2025
Prevalence of Sleep Apnea and Echocardiographic Correlates in a Community-Based Cohort of Cardio-Oncology PatientsMini K Das, John L Huber, Jamie D Kemp, et al.
Cancer Research|September 6, 2005
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cellsMikael Altun, Paul J Galardy, Reshma Shringarpure, et al.
Oncogene|April 20, 2004
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Dharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2013
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cellsDharminder Chauhan, Arghya Ray, Kristina Viktorsson, et al.
Oncotarget|November 9, 2017
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.
Cancer Research|June 17, 2006
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132Lisa J A Crawford, Brian Walker, Huib Ovaa, et al.
Pageof 87